Soluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles

被引：22
作者：
Lee, Youri [1 ,2 ]
Lee, Young-Tae [1 ]
Ko, Eun-Ju [1 ]
Kim, Ki-Hye [1 ]
Hwang, Hye Suk [1 ]
Park, Soojin [1 ]
Kwon, Young-Man [1 ]
Kang, Sang Moo [1 ,2 ]
机构：
[1] Georgia State Univ, Inst Biomed Sci, Ctr Inflammat Immun & Infect, Atlanta, GA 30303 USA
[2] Georgia State Univ, Dept Biol, Inst Biomed Sci, Atlanta, GA USA
来源：
HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2017年 / 13卷 / 11期
关键词：
enhanced disease; F protein; respiratory syncytial virus; safety; virus-like particle; IMMUNE-RESPONSES; COTTON RATS; CPG OLIGODEOXYNUCLEOTIDE; CONFERS PROTECTION; FUSION PROTEIN; GLYCOPROTEIN; RSV; DISEASE; MICE; IMMUNIZATION;
D O I：
10.1080/21645515.2017.1362514
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Respiratory syncytial virus (RSV) fusion (F) protein is suggested to be a protective vaccine target although its efficacy and safety concerns remain not well understood. We investigated immunogenicity, efficacy, and safety of F proteins in a soluble form or on virus-like particle (F-VLP). F VLP preferentially elicited IgG2a antibody and T helper type 1 (Th1) immune responses whereas F protein induced IgG1 isotype and Th2 responses. Despite lung viral clearance after prime or prime-boost and then RSV challenge, F protein immune mice displayed weight loss and lung histopathology and high mucus production and eosinophils. In contrast, prime or prime-boost vaccination of F VLP induced effective protection, prevented infiltration of eosinophils and vaccine- enhanced disease after challenge. This study provides insight into developing an effective and safe RSV vaccine candidate.
引用
收藏
页码：2594 / 2605
页数：12
相关论文
共 43 条
  • [1] Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants
    Boeckh, M
    Berrey, MM
    Bowden, RA
    Crawford, SW
    Balsley, J
    Corey, L
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2001, 184 (03) : 350 - 354
  • [2] FIELD EVALUATION OF A RESPIRATORY SYNCYTIAL VIRUS VACCINE AND A TRIVALENT PARAINFLUENZA VIRUS VACCINE IN A PEDIATRIC POPULATION
    CHIN, J
    MAGOFFIN, RL
    SHEARER, LA
    SCHIEBLE, JH
    LENNETTE, EH
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 1969, 89 (04) : 449 - +
  • [3] COTTON RATS PREVIOUSLY IMMUNIZED WITH A CHIMERIC RSV FG GLYCOPROTEIN DEVELOP ENHANCED PULMONARY PATHOLOGY WHEN INFECTED WITH RSV, A PHENOMENON NOT ENCOUNTERED FOLLOWING IMMUNIZATION WITH VACCINIA RSV RECOMBINANTS OR RSV
    CONNORS, M
    COLLINS, PL
    FIRESTONE, CY
    SOTNIKOV, AV
    WAITZE, A
    DAVIS, AR
    HUNG, PP
    CHANOCK, RM
    MURPHY, BR
    [J]. VACCINE, 1992, 10 (07) : 475 - 484
  • [4] A Role for the Chemokine RANTES in Regulating CD8 T Cell Responses during Chronic Viral Infection
    Crawford, Alison
    Angelosanto, Jill Marie
    Nadwodny, Kim Lynn
    Blackburn, Shawn D.
    Wherry, E. John
    [J]. PLOS PATHOGENS, 2011, 7 (07)
  • [5] Cotton rat immune responses to virus-like particles containing the pre-fusion form of respiratory syncytial virus fusion protein
    Cullen, Lori McGinnes
    Blanco, Jorge C. G.
    Morrison, Trudy G.
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2015, 13
  • [6] Monocyte Chemoattractant Protein-1 (MCP-1): An Overview
    Deshmane, Satish L.
    Kremlev, Sergey
    Amini, Shohreh
    Sawaya, Bassel E.
    [J]. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2009, 29 (06) : 313 - 326
  • [7] Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease
    Florencia Delgado, Maria
    Coviello, Silvina
    Clara Monsalvo, A.
    Melendi, Guillermina A.
    Zea Hernandez, Johanna
    Batalle, Juan P.
    Diaz, Leandro
    Trento, Alfonsina
    Chang, Herng-Yu
    Mitzner, Wayne
    Ravetch, Jeffrey
    Melero, Jose A.
    Irusta, Pablo M.
    Polack, Fernando P.
    [J]. NATURE MEDICINE, 2009, 15 (01) : 34 - 41
  • [8] RESPIRATORY VIRUS IMMUNIZATION .I. A FIELD TRIAL OF 2 INACTIVATED RESPIRATORY VIRUS VACCINES - AN AQUEOUS TRIVALENT PARAINFLUENZA VIRUS VACCINE AND AN ALUM-PRECIPITATED RESPIRATORY SYNCYTIAL VIRUS VACCINE
    FULGINITI, VA
    ELLER, JJ
    SIEBER, OF
    JOYNER, JW
    MINAMITANI, M
    MEIKLEJOHN, G
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 1969, 89 (04) : 435 - +
  • [9] Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles
    Garlapati, S.
    Garg, R.
    Brownlie, R.
    Latimer, L.
    Simko, E.
    Hancock, R. E. W.
    Babiuk, L. A.
    Gerdts, V.
    Potter, A.
    Littel-van den Hurk, S. van Drunen
    [J]. VACCINE, 2012, 30 (35) : 5206 - 5214
  • [10] Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults
    Green, C. A.
    Scarselli, E.
    Voysey, M.
    Capone, S.
    Vitelli, A.
    Nicosia, A.
    Cortese, R.
    Thompson, A. J.
    Sande, C. S.
    de Lara, Catherine
    Klenerman, P.
    Pollard, A. J.
    [J]. BMJ OPEN, 2015, 5 (10):
12345